Interpace Biosciences Inc (PK:IDXG)

Sector:  Healthcare Industry:  Managed Health Care
 
See Regulatory Filings on SEC
Company Contact
Address: Waterview Plaza
Suite 310, 2001 Route 46
PARSIPPANY NJ 07054
Tel: N/A
Website: https://www.interpace.com
IR: See website
<
Key People
Thomas W. Burnell
President, Chief Executive Officer, Director
Christopher Mccarthy
Chief Financial Officer
 
Business Overview
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.
Financial Overview
For the fiscal year ended 31 December 2023, Interpace Biosciences Inc revenues increased 26% to $40.2M. Net income before extraordinary items totaled $1.1M vs. loss of $5.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Selling/General/Admin. Exp decrease of 15% to $9.4M (expense), Other expense, net decrease of 45% to $667K (expense).
Employees: 108 as of Feb 29, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $58.81M as of Dec 31, 2023
Annual revenue (TTM): $40.21M as of Dec 31, 2023
EBITDA (TTM): $3.83M as of Dec 31, 2023
Net annual income (TTM): $1.11M as of Dec 31, 2023
Free cash flow (TTM): $3.32M as of Dec 31, 2023
Net Debt Last Fiscal Year: $5.85M as of Dec 31, 2023
Shares outstanding: 4,376,398 as of Mar 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.